

---

**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**SCHEDULE 13D**

Under the Securities Exchange Act of 1934

**(Amendment No. 5)\***

**Tempest Therapeutics, Inc.**

---

**(Name of Issuer)**

**Common Stock, par value \$0.001 per share**

---

**(Title of Class of Securities)**

**87978U108**

---

**(CUSIP Number)**

**Max Eisenberg  
One Sansome Street, Suite 1650,  
San Francisco, CA, 94104  
415-801-8100**

---

**(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)**

**11/12/2024**

---

**(Date of Event Which Requires Filing of This Statement)**

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

**SCHEDULE 13D**

**CUSIP No. 87978U108**

Name of reporting person

1

Versant Venture Capital VI, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

3 SEC use only  
Source of funds (See Instructions)

4 WC  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5   
Citizenship or place of organization

6 DELAWARE  
Sole Voting Power  
7  
Number of Shares Beneficially Owned by Each Reporting Person With: 209,914.00  
Shared Voting Power  
8  
0.00  
Sole Dispositive Power  
9  
209,914.00  
Shared Dispositive Power  
10  
0.00

11 Aggregate amount beneficially owned by each reporting person  
209,914.00  
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12   
Percent of class represented by amount in Row (11)

13 0.5 %  
Type of Reporting Person (See Instructions)

14 PN

**Comment for Type of Reporting Person:** This Schedule 13D is filed by Versant Venture Capital IV, L.P. ("Versant IV"), Versant Side Fund IV, L.P. ("Side Fund IV"), Versant Ventures IV, LLC ("LLC IV"), Versant Venture Capital VI, L.P. ("Versant VI"), Versant Ventures VI GP, L.P. ("GP VI"), Versant Ventures VI GP-GP, LLC ("LLC VI"), Versant Vantage II, L.P. ("Vantage II LP"), Versant Vantage II GP, L.P. ("Vantage II GP"), Versant Vantage II GP-GP, LLC ("Vantage II LLC" and, with Versant IV, Side Fund IV, LLC IV, Versant VI, GP VI, LLC VI, Vantage II LP and Vantage II GP, collectively, the "Reporting Persons"). LLC IV is the general partner of Versant IV and Side Fund IV, and LLC IV has voting, investment and dispositive power over the shares held by each of Versant IV and Side Fund IV. LLC VI is the general partner of GP VI, which is the general partner of Versant VI. Each of LLC VI and GP VI share voting, investment and dispositive power over the shares held by Versant VI. Vantage II LLC is the general partner of Vantage II GP, which is the general partner of Vantage II LP. Each of Vantage II LLC and Vantage II GP share voting, investment and dispositive power over the shares held by Vantage II LP. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D. These shares are held by Versant VI. LLC VI is the general partner of GP VI, which is the general partner of Versant VI. Each of LLC VI and GP VI share voting, investment and dispositive power over the shares held by Versant VI and as a result may be deemed to have beneficial ownership over such securities. Percentage based on 44,148,563 shares of Common Stock (as defined in Item 1 of the Original Schedule 13D (as defined in Item 1 below)) outstanding as of January 30, 2025, as set forth in the Issuer's prospectus supplement, filed pursuant to Rule 424(b)(5) with the United States Securities and Exchange Commission (the "Commission") on February 6, 2025 (the "Prospectus").

## SCHEDULE 13D

CUSIP No. 87978U108

1 Name of reporting person

Versant Ventures VI GP, L.P.

Check the appropriate box if a member of a Group (See Instructions)

2

(a)

(b)

3

SEC use only

Source of funds (See Instructions)

4

AF

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

DELAWARE

Sole Voting Power

7

0.00

Number of  
Shares

Shared Voting Power

Beneficially 8

Owned by

209,914.00

Each

Sole Dispositive Power

Reporting 9

Person

0.00

With:

Shared Dispositive Power

10

209,914.00

Aggregate amount beneficially owned by each reporting person

11

209,914.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

0.5 %

Type of Reporting Person (See Instructions)

14

PN

**Comment for Type of Reporting Person:** This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D. These shares are held by Versant VI. LLC VI is the general partner of GP VI, which is the general partner of Versant VI. Each of LLC VI and GP VI share voting, investment and dispositive power over the shares held by Versant VI and as a result may be deemed to have beneficial ownership over such securities. Percentage based on 44,148,563 shares of Common Stock outstanding as of January 30, 2025, as set forth in the Prospectus.

## SCHEDULE 13D

**CUSIP No.** 87978U108

Name of reporting person

1

Versant Ventures VI GP-GP, LLC

Check the appropriate box if a member of a Group (See Instructions)

2

(a)

(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

DELAWARE

Sole Voting Power

7

0.00

Number of Shares

Shared Voting Power

Beneficially Owned by

8

209,914.00

Each

Sole Dispositive Power

Reporting Person

9

0.00

With:

Shared Dispositive Power

10

209,914.00

Aggregate amount beneficially owned by each reporting person

11

209,914.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

0.5 %

Type of Reporting Person (See Instructions)

14

OO

**Comment for Type of Reporting Person:** This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D. These shares are held by Versant VI. LLC VI is the general partner of GP VI, which is the general partner of Versant VI. Each of LLC VI and GP VI share voting, investment and dispositive power over the shares held by Versant VI and as a result may be deemed to have beneficial ownership over such securities. Percentage based on 44,148,563 shares of Common Stock outstanding as of January 30, 2025, as set forth in the Prospectus.

### SCHEDULE 13D

**CUSIP No.** 87978U108

Name of reporting person

1

Versant Vantage II, L.P.

Check the appropriate box if a member of a Group (See Instructions)

2

(a)

(b)

3

SEC use only

Source of funds (See Instructions)

4

WC

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power
	2,118,644.00	
		Shared Voting Power
	8	
	0.00	
		Sole Dispositive Power
	9	
	2,118,644.00	
		Shared Dispositive Power
	10	
	0.00	
		Aggregate amount beneficially owned by each reporting person
11	2,118,644.00	
12		Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
	<input type="checkbox"/>	
		Percent of class represented by amount in Row (11)
13	4.8 %	
14		Type of Reporting Person (See Instructions)
	PN	

**Comment for Type of Reporting Person:** This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D. These shares are held by Vantage II LP. Vantage II LLC is the general partner of Vantage II GP, which is the general partner of Vantage II LP. Each of Vantage II LLC and Vantage II GP share voting, investment and dispositive power over the shares held by Vantage II LP and as a result may be deemed to have beneficial ownership over such securities. Percentage based on 44,148,563 shares of Common Stock outstanding as of January 30, 2025, as set forth in the Prospectus.

## SCHEDULE 13D

**CUSIP No.** 87978U108

1	Name of reporting person
	Versant Vantage II GP, L.P.
	Check the appropriate box if a member of a Group (See Instructions)
2	<input type="checkbox"/> (a)
	<input checked="" type="checkbox"/> (b)
3	SEC use only
4	Source of funds (See Instructions)
	AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
	<input type="checkbox"/>
6	Citizenship or place of organization
	DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power
	0.00	
		Shared Voting Power
	8	
	2,118,644.00	
	9	Sole Dispositive Power

0.00  
 Shared Dispositive Power  
 10  
 2,118,644.00  
 11 Aggregate amount beneficially owned by each reporting person  
 2,118,644.00  
 12 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)  
  
 13 Percent of class represented by amount in Row (11)  
 4.8 %  
 Type of Reporting Person (See Instructions)  
 14  
 PN

**Comment for Type of Reporting Person:** This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D. These shares are held by Vantage II LP. Vantage II LLC is the general partner of Vantage II GP, which is the general partner of Vantage II LP. Each of Vantage II LLC and Vantage II GP share voting, investment and dispositive power over the shares held by Vantage II LP and as a result may be deemed to have beneficial ownership over such securities. Percentage based on 44,148,563 shares of Common Stock outstanding as of January 30, 2025, as set forth in the Prospectus.

## SCHEDULE 13D

**CUSIP No.** 87978U108

1 Name of reporting person  
 Versant Vantage II GP-GP, LLC  
 Check the appropriate box if a member of a Group (See Instructions)  
 2  (a)  
 (b)  
 3 SEC use only  
 Source of funds (See Instructions)  
 4  
 AF  
 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)  
 5   
 Citizenship or place of organization  
 6  
 DELAWARE  
 Sole Voting Power  
 7  
 Number of Shares Beneficially Owned by Each Reporting Person With:  
 8  
 0.00  
 Shared Voting Power  
 2,118,644.00  
 Sole Dispositive Power  
 9  
 0.00  
 Shared Dispositive Power  
 10  
 2,118,644.00  
 11 Aggregate amount beneficially owned by each reporting person

2,118,644.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

4.8 %

Type of Reporting Person (See Instructions)

14

OO

**Comment** This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D. These shares are held by Vantage II LP. Vantage II LLC is the general partner of Vantage II GP, which is the general partner of Vantage II LP. Each of Vantage II LLC and Vantage II GP share voting, investment and dispositive power over the shares held by Vantage II LP and as a result may be deemed to have beneficial ownership over such securities. Percentage based on 44,148,563 shares of Common Stock outstanding as of January 30, 2025, as set forth in the Prospectus.

### SCHEDULE 13D

**CUSIP No.** 87978U108

Name of reporting person

1

Versant Venture Capital IV, L.P.

Check the appropriate box if a member of a Group (See Instructions)

2

(a)

(b)

3

SEC use only

Source of funds (See Instructions)

4

WC

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

DELAWARE

Sole Voting Power

7

1,171,094.00

Number of Shares

Shared Voting Power

Beneficially 8

0.00

Owned by

Sole Dispositive Power

Each

Reporting 9

1,171,094.00

Person

With:

Shared Dispositive Power

10

0.00

Aggregate amount beneficially owned by each reporting person

11

1,171,094.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

2.7 %

14 Type of Reporting Person (See Instructions)

PN

**Comment** This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D. These shares are held by Versant IV. LLC IV is the general partner of Versant IV and has voting, investment and dispositive power over the shares held by Versant IV and as a result may be deemed to have beneficial ownership over such securities. Percentage based on 44,148,563 shares of Common Stock outstanding as of January 30, 2025, as set forth in the Prospectus.

### SCHEDULE 13D

**CUSIP No.** 87978U108

Name of reporting person

1 Versant Side Fund IV, L.P.

Check the appropriate box if a member of a Group (See Instructions)

2  (a)  
 (b)

3 SEC use only

Source of funds (See Instructions)

4 WC

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6 DELAWARE

Sole Voting Power

7  
Number of Shares Beneficially Owned by Each Reporting Person With:

7,377.00  
Shared Voting Power

8

0.00  
Sole Dispositive Power

9

7,377.00  
Shared Dispositive Power

10

0.00

Aggregate amount beneficially owned by each reporting person

11 7,377.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13 0.0 %

Type of Reporting Person (See Instructions)

14 PN

**Comment** This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D. These shares are held by Side Fund IV. LLC IV is the general partner of Side Fund IV and has voting, investment and dispositive power over the shares held by Side Fund IV and as a result may be deemed to have beneficial ownership over such securities. Percentage based on 44,148,563 shares of Common Stock outstanding as of January 30, 2025, as set forth in the Prospectus.

SCHEDULE 13D

CUSIP No. 87978U108

1 Name of reporting person  
Versant Ventures IV, LLC  
Check the appropriate box if a member of a Group (See Instructions)

2  (a)  
 (b)

3 SEC use only  
Source of funds (See Instructions)

4 AF  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5   
Citizenship or place of organization

6 DELAWARE  
Sole Voting Power  
7 0.00  
Number of Shares Beneficially Owned by Each Reporting Person With:  
8 Shared Voting Power  
1,178,471.00  
9 Sole Dispositive Power  
0.00  
10 Shared Dispositive Power  
1,178,471.00  
Aggregate amount beneficially owned by each reporting person

11 1,178,471.00  
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12   
Percent of class represented by amount in Row (11)

13 2.7 %  
Type of Reporting Person (See Instructions)

14 OO

**Comment for Type of Reporting Person:** This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D. Includes (i) 1,171,094 shares held by Versant IV; and (ii) 7,377 shares held by Side Fund IV. LLC IV is the general partner of Versant IV and Side Fund IV, and LLC IV has voting, investment and dispositive power over the shares held by each of Versant IV and Side Fund IV and as a result may be deemed to have beneficial ownership over such securities. Percentage based on 44,148,563 shares of Common Stock outstanding as of January 30, 2025, as set forth in the Prospectus.

SCHEDULE 13D

Item 1. Security and Issuer  
(a) Title of Class of Securities:

Common Stock, par value \$0.001 per share

Name of Issuer:

(b)

Tempest Therapeutics, Inc.

Address of Issuer's Principal Executive Offices:

(c)

2000 Sierra Point Parkway, Suite 400, Brisbane, CALIFORNIA , 94005.

**Item 1** This Amendment No. 5 (this "Amendment") amends and supplements the Schedule 13D originally filed by the  
**Comment:** Reporting Persons with the Commission on May 9, 2022, as amended by Amendment No. 1 filed with the Commission on November 9, 2023, Amendment No. 2 filed with the Commission on February 8, 2024, Amendment No. 3 filed with the Commission on May 13, 2024 and Amendment No. 4 ("Amendment No. 4") filed with the Commission on August 12, 2024 (collectively, the "Original Schedule 13D"). Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13D remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment have the meanings ascribed to them in the Original Schedule 13D. This Amendment is being filed to update the aggregate percentage of Common Stock owned by the Reporting Persons due to dilution caused by the Issuer's sales of additional shares of its Common Stock from time to time since the date of the filing of Amendment No. 4. Such transactions resulted in a decrease of over one percent (1%) in the aggregate percentage ownership reported by the Reporting Persons in Amendment No. 4.

#### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Versant Venture Capital VI, L.P.

Signature: /s/Max Eisenberg

Name/Title: Max Eisenberg/Chief Operating Officer of  
Versant Ventures VI GP-GP, LLC, the General  
Partner of Versant Ventures VI GP, L.P.

Date: 02/11/2025

Versant Ventures VI GP, L.P.

Signature: /s/Max Eisenberg

Name/Title: Max Eisenberg/Chief Operating Officer of  
Versant Ventures VI GP-GP, LLC, the General  
Partner of Versant Ventures VI GP, L.P.

Date: 02/11/2025

Versant Ventures VI GP-GP, LLC

Signature: /s/Max Eisenberg

Name/Title: Max Eisenberg/Chief Operating Officer

Date: 02/11/2025

Versant Vantage II, L.P.

Signature: /s/Max Eisenberg

Name/Title: Max Eisenberg/Chief Operating Officer of  
Versant Ventures II GP-GP, LLC, the General  
Partner of Versant Vantage II GP, L.P., the General  
Partner of Ve

Date: 02/11/2025

Versant Vantage II GP, L.P.

Signature: /s/Max Eisenberg

Name/Title: Max Eisenberg/Chief Operating Officer of  
Versant Vantage II GP-GP, LLC, the General  
Partner of Versant Vantage II GP, L.P.

Date: 02/11/2025

Versant Vantage II GP-GP, LLC

Signature: /s/Max Eisenberg

Name/Title: Max Eisenberg/Chief Operating Officer

Date: 02/11/2025

Versant Venture Capital IV, L.P.

Signature: /s/Max Eisenberg

Max Eisenberg/Chief Operating Officer of

Name/Title: Versant Ventures IV, LLC, the General Partner of  
Versant Venture Capital IV, L.P.

Date: 02/11/2025

Versant Side Fund IV, L.P.

Signature: /s/Max Eisenberg

Max Eisenberg/Chief Operating Officer of

Name/Title: Versant Ventures IV, LLC, the General Partner of  
Versant Side Fund IV, L.P.

Date: 02/11/2025

Versant Ventures IV, LLC

Signature: /s/Max Eisenberg

Name/Title: Max Eisenberg/Chief Operating Officer

Date: 02/11/2025